Search

Your search keyword '"Adhikary, Gautam"' showing total 233 results
Start Over Author "Adhikary, Gautam"
233 results on '"Adhikary, Gautam"'

2. Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients

Author

Leonard, M. Kathryn, Puts, Gemma S., Pamidimukkala, Nidhi, Adhikary, Gautam, Xu, Yili, Kwok, Eric, Jin, Yuxin, Snyder, Devin, Matsangos, Nicolette, Novak, Marián, Mahurkar, Anup, Shetty, Amol C., Slominski, Radomir M., De Fabo, Edward C., Noonan, Frances P., Day, Chi-Ping, Rigi, Mohammed, Slominski, Andrzej T., Webb, Michelle G., Craig, David W., Merlino, Glenn, Eckert, Richard L., Carpten, John D., Manojlovic, Zarko, and Kaetzel, David M.

Published
2021
Full Text
View/download PDF

3. Embryonic AP1 Transcription Factor Deficiency Causes a Collodion Baby-Like Phenotype

Author

Young, Christina A, Eckert, Richard L, Adhikary, Gautam, Crumrine, Debra, Elias, Peter M, Blumenberg, Miroslav, and Rorke, Ellen A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Genetics, Underpinning research, 2.1 Biological and endogenous factors, Aetiology, 1.1 Normal biological development and functioning, Animals, Animals, Newborn, Biopsy, Needle, Cell Differentiation, Cells, Cultured, Disease Models, Animal, Filaggrin Proteins, Humans, Ichthyosiform Erythroderma, Congenital, Immunohistochemistry, Intermediate Filament Proteins, Keratinocytes, Mice, Mice, Transgenic, Phenotype, Random Allocation, Sensitivity and Specificity, Signal Transduction, Transcription Factor AP-1, Oncology and Carcinogenesis, Dermatology & Venereal Diseases, Clinical sciences
Abstract

AP1 transcription factors are important controllers of gene expression in the epidermis, and altered AP1 factor function can perturb keratinocyte proliferation and differentiation. However, our understanding of how AP1 signaling changes may underlie or exacerbate skin disease is limited. We have shown that inhibiting AP1 factor function in suprabasal adult epidermis leads to reduced filaggrin levels and to a phenotype that resembles the genetic disorder ichthyosis vulgaris. We now show that inhibiting AP1 factor function during development in embryonic epidermis produces marked phenotypic changes including reduced filaggrin mRNA and protein levels, compromised barrier function, marked ultrastructural change, and enhanced dehydration susceptibility that resembles the phenotype observed in the flaky tail mouse, a model for ichthyosis vulgaris. In addition, the AP1 factor-deficient newborn mice display a collodion membrane phenotype that is not observed in flaky tail mice or in newborn individuals with ichthyosis vulgaris but is present in other forms of ichthyosis. This mixed phenotype suggests the need for a better understanding of the possible role of filaggrin loss and AP1 transcription factor deficiency in ichthyoses and collodion membrane formation.

Published
2017

7. Cell-Impermeable Inhibitors Confirm That Intracellular Human Transglutaminase 2 Is Responsible for the Transglutaminase-Associated Cancer Phenotype

Author

Gates, Eric W. J., primary, Calvert, Nicholas D., additional, Cundy, Nicholas J., additional, Brugnoli, Federica, additional, Navals, Pauline, additional, Kirby, Alexia, additional, Bianchi, Nicoletta, additional, Adhikary, Gautam, additional, Shuhendler, Adam J., additional, Eckert, Richard L., additional, and Keillor, Jeffrey W., additional

Published
2023
Full Text
View/download PDF

8. Correction: Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients

Author

Leonard, M. Kathryn, Puts, Gemma S., Pamidimukkala, Nidhi, Adhikary, Gautam, Xu, Yili, Kwok, Eric, Jin, Yuxin, Snyder, Devin, Matsangos, Nicolette, Novak, Marián, Mahurkar, Anup, Shetty, Amol C., Slominski, Radomir M., De Fabo, Edward C., Noonan, Frances P., Day, Chi-Ping, Rigi, Mohammed, Slominski, Andrzej T., Webb, Michelle G., Craig, David W., Merlino, Glenn, Eckert, Richard L., Carpten, John D., Manojlovic, Zarko, and Kaetzel, David M.

Published
2021
Full Text
View/download PDF

11. Novel irreversible peptidic inhibitors of transglutaminase 2

Author

Cundy, Nicholas J., primary, Arciszewski, Jane, additional, Gates, Eric W. J., additional, Acton, Sydney L., additional, Passley, Kyle D., additional, Awoonor-Williams, Ernest, additional, Boyd, Elizabeth K., additional, Xu, Nancy, additional, Pierson, Élise, additional, Fernandez-Ansieta, Catalina, additional, Albert, Marie R., additional, McNeil, Nicole M. R., additional, Adhikary, Gautam, additional, Eckert, Richard L., additional, and Keillor, Jeffrey W., additional

Published
2023
Full Text
View/download PDF

18. Intracellular Pathways Linking Hypoxia to Activation of c-fos and AP-1

Author

Premkumar, Daniel R., Adhikary, Gautam, Overholt, Jeffery L., Simonson, Michael S., Cherniack, Neil S., Prabhakar, Nanduri R., Back, Nathan, editor, Cohen, Irun R., editor, Kritchevsky, David, editor, Lajtha, Abel, editor, Paoletti, Rodolfo, editor, Lahiri, Sukhamay, editor, Prabhakar, Naduri R., editor, and Forster, Robert E., II, editor

Published
2002
Full Text
View/download PDF

26. Sulforaphane covalently interacts with the transglutaminase 2 cancer maintenance protein to alter its structure and suppress its activity

Author

Rorke, Ellen A., primary, Adhikary, Gautam, additional, Szmacinski, Henryk, additional, Lakowicz, Joseph R., additional, Weber, David J., additional, Godoy‐Ruiz, Raquel, additional, Puranik, Purushottamachar, additional, Keillor, Jeffrey W., additional, Gates, Eric W. J., additional, and Eckert, Richard L., additional

Published
2021
Full Text
View/download PDF

35. Novel irreversible peptidic inhibitors of transglutaminase 2Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d2md00417h

Author

Cundy, Nicholas J., Arciszewski, Jane, Gates, Eric W. J., Acton, Sydney L., Passley, Kyle D., Awoonor-Williams, Ernest, Boyd, Elizabeth K., Xu, Nancy, Pierson, Élise, Fernandez-Ansieta, Catalina, Albert, Marie R., McNeil, Nicole M. R., Adhikary, Gautam, Eckert, Richard L., and Keillor, Jeffrey W.

Abstract

Transglutaminase 2 (TG2), also referred to as tissue transglutaminase, plays crucial roles in both protein crosslinking and cell signalling. It is capable of both catalysing transamidation and acting as a G-protein, these activities being conformation-dependent, mutually exclusive, and tightly regulated. The dysregulation of both activities has been implicated in numerous pathologies. TG2 is expressed ubiquitously in humans and is localized both intracellularly and extracellularly. Targeted TG2 therapies have been developed but have faced numerous hurdles including decreased efficacy in vivo. Our latest efforts in inhibitor optimization involve the modification of a previous lead compound's scaffold by insertion of various amino acid residues into the peptidomimetic backbone, and derivatization of the N-terminus with substituted phenylacetic acids, resulting in 28 novel irreversible inhibitors. These inhibitors were evaluated for their ability to inhibit TG2 in vitroand their pharmacokinetic properties, and the most promising candidate 35(kinact/KI= 760 × 103M−1min−1) was tested in a cancer stem cell model. Although these inhibitors display exceptional potency versusTG2, with kinact/KIratios nearly ten-fold higher than their parent compound, their pharmacokinetic properties and cellular activity limit their therapeutic potential. However, they do serve as a scaffold for the development of potent research tools.

Published
2023
Full Text
View/download PDF

46. Regulation of Involucrin Gene Expression

Author

Eckert, Richard L., Crish, James F., Efimova, Tatiana, Dashti, Shervin R., Deucher, Anne, Bone, Frederic, Adhikary, Gautam, Huang, Guosheng, Gopalakrishnan, Ramamurthy, and Balasubramanian, Sivaprakasam

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results